Discrepant MR and [18F]Fluoroethyl-L-Tyrosine PET imaging findings in a patient with bevacizumab failure

Galldiks, N.; Goldbrunner, R.; Filss, C.P.; Langen, K.-J.

doi:10.1159/000342480

Journal Article

PreJuSER-22775

Discrepant MR and [18F]Fluoroethyl-L-Tyrosine PET imaging findings in a patient with bevacizumab failure

Galldiks, N.FZJ* ; Filss, C. P.FZJ* ; Goldbrunner, R. ; Langen, K.-J.FZJ*

2012
Karger Basel

Case reports in oncology 5, 490 - 494 (2012) [10.1159/000342480]

This record in other databases:

Please use a persistent id in citations: http://hdl.handle.net/2128/11529 doi:10.1159/000342480

Abstract: Photodynamic therapy (PDT) has become a well-established treatment for vascular forms of age-related macular degeneration (AMD). The implementation of evidence-based medicine principles into the treatment regimen of AMD seems to be immensly important, since AMD continues to be the most frequent cause of blindness among patients older than 65 years in industrialized countries. Numerous randomized prospective studies demonstrated high levels of evidence for the efficacy of various treatment approaches such as laser photocoagulation, PDT, subretinal surgery or novel anti-angiogenic drugs [Arch Ophthalmol 2006;124:597-599]. The high evidence shown by these studies supported the rationale to use PDT also in additional, less frequent, vasoproliferative diseases. Although these 'case series' and 'individual case control studies' have a low level of evidence, they give us important information for treatment decisions in these rare conditions. The goal of this survey is to review the current literature regarding PDT in vasoproliferative and exudative ocular diseases outside AMD. Many studies modified the treatment parameters of PDT to address the specific pathology of the underlying disease. Table 1 summarizes the diseases and treatment parameters that are described in this part 2, the entire table of this review is included in part 1 (www.karger.com/doi/10.1159/ 000101922).

Keyword(s): Exudates and Transudates: metabolism (MeSH) ; Eye Diseases: drug therapy (MeSH) ; Eye Diseases: metabolism (MeSH) ; Eye Neoplasms: drug therapy (MeSH) ; Humans (MeSH) ; Neovascularization, Pathologic: drug therapy (MeSH) ; Photochemotherapy: trends (MeSH)